Megha Bhumralkar is a registered patent agent with more than 20 years of experience in developing and managing patent portfolios in the areas of pharmaceuticals, biotechnology, chemistry, and the food industry. She has drafted and prosecuted patent applications for small molecule pharmaceuticals, drug conjugates, and formulations in patent portfolios covering clinical candidates and approved products for several biotechnology and pharmaceutical companies. Representative clients include Bristol Myers Squibb, Daiichi Sankyo, Biogen, Acorda Pharmaceuticals, Bunge Limited, and academic institutions. Particular small molecule pharmaceuticals that Megha has been involved with include, IDHIFA®, THELIN®, Quizartinib, Eragidomide, Emricasan, and Vosaroxin.
In addition to patent procurement and portfolio management, Megha advises clients regarding patentability, Orange Book listing, patent life cycle management, validity, infringement, and freedom-to-operate issues; and she performs due diligence evaluations of patent portfolios for possible licensing or acquisition.
Before joining Jones Day, Megha was a technology specialist in the San Diego offices of several IP-centered law firms. Prior to entering the intellectual property field, she was a postdoctoral research fellow at the University of California, San Diego where her research involved synthetic collagen mimetics. She worked extensively on small molecule heterocycles during her graduate studies.
经验
- Nagpur University, India (Ph.D. in Organic Chemistry 1997; M.Sc. in Chemistry 1990; B.Sc. in Chemistry 1988)
- Registered to practice before the United States Patent and Trademark Office. Not licensed to practice by the State Bar of California.
发送前请注意
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice